This content is machine translated Type 2 diabetes and cardiovascular disease How to reduce the burden of disease and improve prognosis Type 2 diabetes is known to increase the risk of cardiovascular disease. The ADA guidelines updated in 2025 propose specific screening measures for heart failure, coronary heart disease and PAD....…
View Post 5 min This content is machine translated Type 2 diabetes and CKD: primary and secondary prevention Screening paves the way for the best possible cardiorenal protection The presence of type 2 diabetes is considered a risk factor for the development of chronic kidney disease (CKD). Simple screening measures based on blood and urine samples can detect...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 5 min This content is machine translated Type 2 diabetes: reduction of microvascular and macrovascular risks The extensive toolbox has a lot to offer The fact that most type 2 diabetics today aim for an HbA1c value of <7% is partly due to the results of the UKPDS. This landmark study showed that the…
View Post 4 min This content is machine translated Type 2 diabetes Patient-oriented and far-sighted treatment A personalized treatment strategy has become an important basic principle in diabetes therapy. In addition to taking into account inter-individual differences in patient characteristics, certain clusters in relation to the…
View Post 4 min This content is machine translated Obesity Incretin mimetics close therapeutic gap Dietary changes and exercise often prove insufficient as measures against morbid obesity. Until now, bariatric surgery has been the only goal-oriented measure for many obese patients. This has changed in…
View Post 5 min This content is machine translated CKD in type 2 diabetes Cardiorenal protection in focus – using modern therapy options Type 2 diabetics can lead a relatively normal life if they adhere to therapy guidelines and maintain HbA1c levels for as many years as possible.are in the target area. Conversely,…
View Post 3 min This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but…
View Post 3 min This content is machine translated GLP-1-RA in type 2 diabetes Broad spectrum of action – weight reduction is also supported GLP-1 receptor agonists promote insulin secretion from pancreatic beta cells, leading to decreased glucose release by the liver and increasing insulin sensitivity. Moreover, they slow down gastric emptying and thus…
View Post 5 min This content is machine translated KDIGO Guidelines 2022 Modern therapy can slow progression of diabetic nephropathy Diabetes is the most common cause of chronic kidney disease (CKD).The international organization Kidney Disease: Improving Global Outcomes (KDIGO) recently released new guidelines on the management of type 2 diabetes…
